China's Kaitai Capital bets big on biomedicine, AI, digital economy

China's Kaitai Capital bets big on biomedicine, AI, digital economy

Yonghong Xu, Kaitai Capital Partner and CEO

Even as Hangzhou-headquartered Kaitai Capital is taking a cautious approach towards fresh investments amidst the COVID-19 pandemic, it is prioritizing funding in its portfolio companies.

In the past few months, it has increased its investments in companies such as ABM Therapeutics (drug maker), Exegenesis Bio (gene editing and genome engineering company), Lupeng Pharmaceutical, and Atom Bioscience and Pharmaceutical, among others.

“We have enhanced and concentrated our investments in the healthcare industry, especially in the field of biomedicine,” said Yonghong Xu,  partner and CEO at Kaitai Capital, in an interaction with DealStreetAsia.

The sectors it covers are oncology, metabolic disorders, cardiovascular risk, anti-infection, autoimmunity, neuroscience, skin disease, and respiratory illness. And within the sector, it spots big promise in next-generation reagents, small molecular targeted drugs, macromolecular anti-body treatments, gene and cell therapies, among others.

The 11-year-old Kaitai Capital currently has 50 billion yuan ($7.5 billion) in assets under management.

Edited excerpts of an interview with Xu:

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter